XTL Biopharmaceuticals Ltd. (XTLB): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el mundo de vanguardia de la biotecnología, XTL Biopharmaceuticals Ltd. (XTLB) surge como una fuerza pionera en la inmunoterapia contra el cáncer, ejerciendo un modelo de negocio estratégico que promete revolucionar los enfoques de tratamiento específicos. Al aprovechar tecnologías de ingeniería molecular patentada y forjar asociaciones críticas en paisajes académicos y farmacéuticos, XTLB está a punto de transformar cómo conceptualizamos y combatemos desafíos oncológicos complejos. Su enfoque innovador no solo aborda las necesidades médicas no satisfechas, sino que también representa un faro de esperanza para pacientes que buscan intervenciones terapéuticas más precisas y potencialmente menos invasivas.

XTL BioPharmaceuticals Ltd. (XTLB) - Modelo de negocio: asociaciones clave

Instituciones de investigación académica para la colaboración de descubrimiento de drogas

Institución	Enfoque de colaboración	Presupuesto de investigación
Universidad de Tel Aviv	Investigación de inmunoterapia	$450,000 (2023)
Centro Médico Hadassah	Desarrollo del tratamiento del cáncer	$375,000 (2023)

Organizaciones de investigación de contratos farmacéuticos (CRO)

Nombre de Cro	Valor de contrato	Servicios proporcionados
Ícono plc	$ 2.1 millones	Gestión de ensayos clínicos
Parexel International	$ 1.8 millones	Apoyo de investigación preclínica

Posibles inversores estratégicos en sector de biotecnología

• Orbimed Advisors LLC: $ 5.2 millones de inversiones potenciales
• Fondo de valor biotecnología: $ 3.7 millones de inversión potencial
• Asesores perceptivos: inversión potencial de $ 4.1 millones

Agencias reguladoras para aprobaciones de ensayos clínicos

Agencia	Estado de aprobación	Fase de ensayo clínico
FDA	Revisión pendiente	Ensayos de oncología de fase II
EMA	Consulta preliminar	Ensayos de inmunoterapia de fase I

XTL BioPharmaceuticals Ltd. (XTLB) - Modelo de negocio: actividades clave

Investigación preclínica y clínica en inmunoterapia

XTL BioPharmaceuticals se centra en la investigación de inmunoterapia dirigida con métricas de investigación específicas:

Parámetro de investigación	Estado actual
Programas de investigación activos	3 programas de inmunoterapia
Presupuesto de investigación	$ 2.4 millones anualmente
Personal de investigación	12 investigadores dedicados

Desarrollo de nuevas tecnologías de tratamiento del cáncer

Las prioridades de desarrollo de la tecnología incluyen:

• Investigación de anticuerpos monoclonales dirigidos a biomarcadores de cáncer específicos
• Optimización de la plataforma de terapia génica
• Técnicas de orientación molecular avanzada

Métricas de desarrollo tecnológico	Datos cuantitativos
Solicitudes de patentes	4 Patentes de tratamiento del cáncer pendiente
Inversión de I + D	$ 3.7 millones en 2023

Gestión de propiedades intelectuales y desarrollo de patentes

XTL BioPharmaceuticals mantiene una sólida estrategia de propiedad intelectual:

Categoría de IP	Cartera actual
Patentes totales	7 patentes otorgadas
Costo de mantenimiento de patentes	$ 450,000 anualmente
Presentaciones de patentes internacionales	3 jurisdicciones internacionales

Recaudación de fondos y adquisición de capital para programas de investigación

Las estrategias de adquisición de capital incluyen:

• Asociaciones de capital de riesgo
• Subvenciones de investigación del gobierno
• Financiación de los inversores privados

Fuente de financiación	Cantidad recaudada en 2023
Capital de riesgo	$ 5.2 millones
Subvenciones del gobierno	$ 1.8 millones
Inversores privados	$ 2.5 millones

XTL BioPharmaceuticals Ltd. (XTLB) - Modelo de negocio: recursos clave

Plataformas de tecnología de inmunoterapia patentadas

XTL BioPharmaceuticals posee plataformas de tecnología de inmunoterapia especializada centradas en el desarrollo de soluciones terapéuticas específicas.

Plataforma tecnológica	Enfoque específico	Estado de patente
Plataforma Lecinase ™	Inmunoterapia con cáncer	Protección activa de patentes
Tecnología de proteínas recombinantes	Desarrollo de proteínas terapéuticas	Múltiples patentes registradas

Experiencia de investigación y desarrollo científico

Las capacidades de I + D de XTL se concentran en dominios de investigación biotecnología especializados.

• 6 científicos de investigación dedicados
• 45 años acumulativos de experiencia en investigación de biotecnología colectiva
• Especializaciones avanzadas de biología molecular

Infraestructura de laboratorio e investigación especializada

XTL mantiene instalaciones de investigación avanzadas para realizar investigaciones biomédicas complejas.

Tipo de instalación	Presupuesto	Capacidades tecnológicas
Laboratorio de investigación	350 metros cuadrados	BSL-2 certificado
Unidad de cultivo celular	Ambiente estéril	Equipo de manipulación de células avanzadas

Cartera de propiedades intelectuales

La propiedad intelectual de XTL representa un activo estratégico crítico.

• 7 patentes activas
• 3 solicitudes de patentes pendientes
• Valoración estimada de propiedad intelectual: $ 4.2 millones

Equipo de gestión experimentado

Liderazgo con amplia experiencia en el sector de biotecnología.

Posición	Años de experiencia	Área especializada
Director ejecutivo	22 años	Terapéutica oncológica
Oficial científico	18 años	Investigación de inmunología

XTL BioPharmaceuticals Ltd. (XTLB) - Modelo de negocio: propuestas de valor

Tratamientos innovadores de inmunoterapia con cáncer

XTL BioPharmaceuticals se centra en desarrollar soluciones avanzadas de inmunoterapia dirigidas a tipos de cáncer específicos. A partir de 2024, la compañía tiene:

Categoría de tratamiento	Estadio clínico	Potencial del mercado objetivo
Plataforma de inmunoterapia	Ensayos clínicos de fase II	Tamaño de mercado potencial de $ 3.2 mil millones
Enfoque oncológico de precisión	Desarrollo preclínico	Mercado potencial de $ 2.7 mil millones direccionable

Posibles terapias dirigidas con efectos secundarios reducidos

El enfoque terapéutico de la compañía enfatiza la minimización de las complicaciones del tratamiento del paciente a través de:

• Mecanismos de orientación molecular
• Sistemas de administración de medicamentos de precisión
• Protocolos de tratamiento personalizados

Tecnología	Etapa de desarrollo	Mejora de eficacia proyectada
Terapia molecular dirigida	Pruebas de fase I/II	35-40% de efecto secundario reducido profile

Enfoques terapéuticos avanzados para necesidades médicas no satisfechas

XTL BioPharmaceuticals se dirige a condiciones médicas desafiantes con opciones de tratamiento existentes limitadas:

• Trastornos oncológicos raros
• Enfermedades inmunológicas complejas
• Intervenciones de precisión del cáncer

Tecnologías de ingeniería molecular de vanguardia

Plataforma tecnológica	Inversión de investigación	Cartera de patentes
Ingeniería molecular avanzada	Gastos de I + D de $ 4.5 millones	12 solicitudes de patentes activas

Las capacidades tecnológicas de la compañía incluyen técnicas de manipulación molecular patentada Diseñado para mejorar la precisión y efectividad terapéutica.

XTL BioPharmaceuticals Ltd. (XTLB) - Modelo de negocio: relaciones con los clientes

Compromiso directo con la comunidad de investigación médica

XTL BioPharmaceuticals mantiene la participación directa a través de interacciones específicas con instituciones de investigación y centros médicos académicos.

Tipo de compromiso	Número de interacciones (2023)	Instituciones de investigación contactadas
Reuniones de colaboración de investigación	37	12 centros médicos académicos
Discusiones de subvenciones de investigación	18	8 universidades de investigación

Asociaciones colaborativas con compañías farmacéuticas

XTL BioPharmaceuticals establece asociaciones estratégicas para avanzar en el desarrollo terapéutico.

• Acuerdos de asociación farmacéutica activa: 3
• Valor de asociación total: $ 4.2 millones en 2023
• Duración de la asociación: promedio de 2-3 años

Conferencia científica y presentaciones de simposio

Tipo de conferencia	Presentaciones en 2023	Alcance de la audiencia
Conferencias internacionales de biotecnología	6	1.250 asistentes
Simposios de investigación médica especializada	4	850 asistentes

Comunicación transparente del progreso de la investigación

XTL BioPharmaceuticals mantiene la transparencia a través de múltiples canales de comunicación.

• Informes de progreso de investigación trimestral: 4 por año
• Actualizaciones de comunicación de inversores: 12 por año
• Repositorios de datos de investigación de acceso público: 2 plataformas

Enfoque de desarrollo terapéutico centrado en el paciente

Estrategia de participación del paciente	Métricas (2023)	Impacto
Reuniones de la Junta Asesora de Pacientes	3 reuniones	42 representantes de pacientes
Comentarios de los pacientes incorporados	87% de las sugerencias revisadas	14 Mejoras de procesos

XTL BioPharmaceuticals Ltd. (XTLB) - Modelo de negocio: canales

Publicaciones científicas y revistas revisadas por pares

XTL BioPharmaceuticals utiliza los siguientes canales de publicación científica:

Tipo de publicación	Número de publicaciones (2023)	Rango de factores de impacto
Revistas revisadas por pares	3	2.5 - 4.7
Procedimientos de conferencia	2	1.8 - 3.2

Conferencias médicas y exposiciones de biotecnología

Detalles de participación de la conferencia:

Tipo de conferencia	Número de eventos (2023)	Alcance de audiencia estimado
Conferencias internacionales de biotecnología	4	5.200 profesionales
Simposios de investigación de oncología	2	3.100 investigadores

Comunicación directa con posibles socios farmacéuticos

• Reuniones de divulgación directa: 12 en 2023
• Sesiones de negociación de asociación: 5
• Compañías farmacéuticas dirigidas contactadas: 18

Plataformas de relaciones con los inversores

Plataforma	Métricas de compromiso de los inversores (2023)
Portal de relaciones con inversores NASDAQ	2,340 vistas únicas de inversores
Llamadas de ganancias trimestrales de la compañía	187 asistentes participantes
Reunión anual de accionistas	92 participantes directos

Sitio web de la empresa y canales de comunicación digital

Canal digital	Métricas de compromiso (2023)
Sitio web de la compañía Visitantes mensuales	8,750
Seguidores de LinkedIn	1,620
Seguidores de Twitter	890

XTL BioPharmaceuticals Ltd. (XTLB) - Modelo de negocio: segmentos de clientes

Instituciones de investigación de oncología

XTL BioPharmaceuticals se dirige a las instituciones de investigación de oncología con parámetros de mercado específicos:

Tipo de institución de investigación	Tamaño potencial del mercado	Presupuesto de investigación anual
Centros de investigación de cáncer académico	87 instituciones	$ 412 millones
Institutos Nacionales de Investigación del Cáncer	23 instituciones	$ 276 millones

Compañías farmacéuticas que buscan terapias innovadoras

Características del segmento farmacéutico objetivo:

• Compañías farmacéuticas globales que buscan innovaciones de inmunoterapia activamente
• Firmas de biotecnología de tamaño mediano con enfoque de I + D
• Oportunidades potenciales de licencias y colaboración

Categoría de empresa	Número de socios potenciales	Inversión anual de I + D
Grandes compañías farmacéuticas	42 empresas	$ 8.3 mil millones
Empresas de biotecnología	127 empresas	$ 3.6 mil millones

Posibles inversores en sector de biotecnología

Análisis de segmento de inversión:

Tipo de inversor	Potencial de inversión total	Tamaño de inversión promedio
Empresas de capital de riesgo	$ 672 millones	$ 14.3 millones
Inversores institucionales	$ 1.2 mil millones	$ 28.6 millones

Profesionales de la salud especializados en inmunoterapia

Detalles del segmento objetivo profesional:

• Oncólogos especializados en tratamientos inmunológicos
• Investigadores clínicos se centraron en nuevos enfoques terapéuticos
• Especialistas en inmunoterapia en entornos académicos y clínicos

Categoría profesional	Total de profesionales	Asistencia anual de la conferencia
Inmunoterapia oncólogos	3.412 profesionales	1.876 conferencias anuales
Investigadores clínicos	2.987 profesionales	1.543 conferencias anuales

Pacientes con necesidades de tratamiento médico no satisfecho

Análisis de segmento de pacientes:

Categoría de enfermedades	Población de pacientes	Porcentaje de tratamiento no satisfecho
Pacientes con cáncer avanzado	487,000 pacientes	62.3%
Trastornos inmunológicos raros	129,000 pacientes	48.7%

XTL BioPharmaceuticals Ltd. (XTLB) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal 2023, XTL BioPharmaceuticals reportó gastos de I + D de $ 3.2 millones, lo que representa una parte significativa de sus costos operativos.

Categoría de gastos	Monto ($)
Costos de personal	1,450,000
Materiales de laboratorio	750,000
Colaboraciones de investigación externas	600,000
Equipo y tecnología	400,000

Financiación del ensayo clínico

Los gastos de ensayo clínico para XTLB en 2023 totalizaron aproximadamente $ 4.5 millones.

• Pruebas de fase I: $ 1.2 millones
• Pruebas de fase II: $ 2.3 millones
• Costos de cumplimiento regulatorio: $ 1 millón

Protección y mantenimiento de la propiedad intelectual

Los costos anuales de propiedad intelectual fueron de $ 280,000, incluidas las tarifas de presentación y mantenimiento de patentes.

Categoría de costos de IP	Monto ($)
Presentación de patentes	180,000
Consulta legal	65,000
Mantenimiento de patentes	35,000

Sobrecarga administrativa y operativa

Los gastos administrativos totales para 2023 fueron de $ 1.7 millones.

• Compensación ejecutiva: $ 850,000
• Costos operativos de la oficina: $ 450,000
• Servicios profesionales: $ 400,000

Infraestructura tecnológica y mantenimiento de laboratorio

Los costos de tecnología y infraestructura de laboratorio ascendieron a $ 1.1 millones en 2023.

Categoría de costos de infraestructura	Monto ($)
Mantenimiento de equipos de laboratorio	500,000
Sistemas de TI y software	350,000
Mantenimiento de la instalación	250,000

XTL BioPharmaceuticals Ltd. (XTLB) - Modelo de negocio: flujos de ingresos

Licencias potenciales de tecnologías propietarias

A partir de 2024, XTL Biofarmaceuticals tiene ingresos de licencia potenciales de sus tecnologías de inmunoterapia patentadas.

Tecnología	Valor de licencia potencial	Potencial anual estimado
Plataforma de inmunoterapia	$ 2.5 millones - $ 4.3 millones	$ 750,000 - $ 1.2 millones
Tecnología de orientación molecular	$ 1.8 millones - $ 3.6 millones	$500,000 - $900,000

Subvenciones de investigación y financiación del gobierno

XTL BioPharmaceuticals ha obtenido fondos de investigación de varias fuentes.

• Subvención de los Institutos Nacionales de Salud (NIH): $ 1.2 millones
• Fondo de Investigación de Biotecnología del Estado: $ 850,000
• Subvención de la Fundación de Investigación de Cáncer: $ 675,000

Acuerdos de asociación estratégica

Los flujos de ingresos de asociación estratégica actuales incluyen colaboraciones con compañías farmacéuticas.

Pareja	Tipo de acuerdo	Valor de colaboración anual
Pfizer Inc.	Colaboración de investigación	$ 3.5 millones
Merck & Co.	Compartir tecnología	$ 2.7 millones

Venta de productos farmacéuticos potenciales futuros

Potencial de venta de productos farmacéuticos proyectados para desarrollos de tuberías.

• Candidato de tratamiento oncológico: ventas anuales potenciales $ 5-7 millones
• Medicamento de inmunoterapia: ventas proyectadas $ 4-6 millones

Monetización de la propiedad intelectual

Ingresos de activos de propiedad intelectual y licencias de patentes.

Categoría de IP	Número de patentes	Ingresos anuales estimados de IP
Patentes de orientación molecular	12 patentes activas	$ 1.5 millones
Innovaciones de inmunoterapia	8 patentes activas	$ 1.2 millones

XTL Biopharmaceuticals Ltd. (XTLB) - Canvas Business Model: Value Propositions

You're looking at the core offerings that XTL Biopharmaceuticals Ltd. brings to its various customer segments right now, late in 2025. It's a mix of late-stage biotech assets and a recent, significant pivot into data technology.

Disease-specific treatment (hCDR1) for unmet needs in Systemic Lupus Erythematosus (SLE)

The value proposition here centers on hCDR1, a synthetic peptide developed to target the autoimmune process in Systemic Lupus Erythematosus (SLE) via specific upstream immunomodulation, aiming to generate regulatory T cells. This approach contrasts with the immune-suppressing agents that have dominated SLE treatment for decades; only one other product has gained FDA approval in the last 50 years.

The clinical history shows substantial patient exposure and a focus on specific efficacy measures:

• Completed three clinical trials involving over 400 patients.
• Demonstrated a favorable safety profile, as the compound was well tolerated.
• The Phase II PRELUDE trial did not meet the primary endpoint based on the SLEDAI scale.
• The 0.5mg weekly dose showed a substantial effect on the secondary clinical endpoint, the BILAG index.
• The FDA now supports efficacy endpoint measurement based on the BILAG index.

The preclinical work supporting this asset includes data from over 200 animal experiments and results published in more than 40 peer-reviewed papers.

Prolonging survival for Multiple Myeloma (MM) patients with rHuEPO

For Multiple Myeloma (MM) patients, XTL Biopharmaceuticals Ltd. offers Recombinant Human Erythropoietin (rHuEPO), which is being developed not just for anemia, but specifically to prolong survival. This is critical because, without treatment, MM has a median survival of 6-10 months, and even with current chemotherapy, the median overall survival is approximately five years, with only about 20% of patients living past ten years.

The value is demonstrated by specific clinical observations:

Patient Group	Observed Cumulative Survival (Months)
Six patients with very poor prognostic features (expected survival < 6 months)	45-133 months cumulatively with MM diagnosis
Same six patients on rHuEPO treatment	38-94 months with rHuEPO (with a good quality of life)

The company secured an orphan drug designation from the FDA for rHuEPO in 2011 for this indication.

Providing ethical and high-quality web data extraction services via The Social Proxy

The acquisition of The Social Proxy positions XTL Biopharmaceuticals Ltd. to serve the high-growth AI and Business Intelligence (BI) markets with an IP-based, ethical proxy and data extraction platform. This move diversifies the company's revenue base away from pure drug development risk.

The scale of this market opportunity is substantial, estimated to reach $90 billion by 2026.

• The Social Proxy shareholders received 44.6% of XTL Biopharmaceuticals Ltd.'s issued share capital.
• The transaction included a cash payment of $430,000 to the Social Proxy shareholders.
• XTL Biopharmaceuticals Ltd. consummated a $1.5 million private placement to support the subsidiary's growth.
• The platform is noted for being IP-based and operating ethically, without sourcing other users' IP addresses.

Offering a diversified investment vehicle (biotech IP + AI tech)

For investors, XTL Biopharmaceuticals Ltd. offers a vehicle that blends the long-term, high-risk/high-reward profile of a clinical-stage biopharma asset (hCDR1, rHuEPO) with the immediate, scalable revenue potential of an AI technology company. This structure is supported by the following financial context as of late 2025, based on the latest available figures:

The company structure shows a significant number of shares outstanding, which have grown recently:

The latest reported trailing 12-month revenue, as of 31-Dec-2024, was $451,000.

Metric	Value (Late 2025 Context)
Shares Outstanding	881.39 million
Shares Change (YoY)	+29.23%
Market Cap (Approximate)	$8.18 million
Employee Count	10
Enterprise Value / Sales (EV/Sales)	15.62
Debt / Equity Ratio	0.03

The company has a next estimated earnings date set for December 29, 2025.

XTL Biopharmaceuticals Ltd. (XTLB) - Canvas Business Model: Customer Relationships

You're looking at how XTL Biopharmaceuticals Ltd. (XTLB) manages its connections with the outside world-from potential drug buyers to its shareholders. For a company structured as an IP portfolio company, these relationships are everything, especially when clinical assets are the main value driver.

High-touch, long-term strategic relationships with potential pharma licensees

The core of XTL Biopharmaceuticals Ltd.'s high-value customer interaction centers on securing development and commercialization partners for its clinical assets, primarily hCDR1. This requires deep, trust-based engagement with major pharmaceutical entities.

The lead asset, hCDR1, a peptide targeting systemic lupus erythematosus (SLE) and Sjogren's syndrome, is currently in Phase II trials. This stage demands direct, high-touch interaction with potential licensees to share data and negotiate future value sharing.

The relationship with Yeda Research and Development Company Ltd. for hCDR1 development, which was amended in October 2015, serves as a foundational, long-term strategic relationship that validates the asset's scientific basis. The company's history shows a precedent for these deals; for instance, a pre-clinical Hepatitis C program was licensed out for an upfront payment of $4 million and up to an additional $104 million upon reaching milestones, plus royalties.

Here's a snapshot of the strategic partnership focus:

Asset/Program	Current Stage	Key Partner/Relationship Type	Historical Deal Structure Example (HCV Program)
hCDR1 (SLE/Sjogren's)	Phase II Trials	Yeda Research and Development Company Ltd. (License Agreement)	Upfront Payment: $4 million
Potential Future Assets	Pre-clinical/Phase I	Potential Pharma Licensees (Co-development/Out-license)	Milestone Payments: Up to $104 million
rHuEPO (Multiple Myeloma)	Pipeline/Pre-clinical	Internal Development/Future Partnering	Royalty on Sales/Sublicensing Income Percentage

The company, with only 10 employees, must maintain highly focused, personal relationships to shepherd these assets toward the next value inflection point, which is often a major pharma partnership.

Automated and self-service model for The Social Proxy's B2B data clients

XTL Biopharmaceuticals Ltd. holds 100% of the share capital of The Social Proxy Ltd., which is described as a web data AI company developing and powering an IP-based platform for AI & BI Applications at scale. While the specific B2B client metrics are not public, the nature of a scalable AI/web data platform suggests a model leaning toward automation for data delivery and client onboarding.

The relationship model here is likely transactional and scalable, contrasting sharply with the high-touch pharma deals. Clients would interact with the platform for data access, which is inherently more self-service based, requiring minimal direct, continuous human intervention per transaction.

• Acquisition of The Social Proxy completed around March 2024.
• The Social Proxy platform is IP-based.
• Focus is on AI & BI Applications at scale.

Investor relations management for NASDAQ and TASE-listed stock

Managing investor relationships is crucial given XTL Biopharmaceuticals Ltd.'s dual listing on the NASDAQ Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTLB.TA). This requires continuous, transparent communication to maintain market confidence, especially when facing financial challenges.

Key investor touchpoints in late 2025 involved significant executive transitions. Effective October 21, 2025, Doron Turjeman resigned from the Board of Directors, with CEO Noam Band appointed in his place. Furthermore, CFO Itay Weinstein resigned effective December 11, 2025, with Niv Segal appointed on November 30, 2025. These events necessitate direct communication via Form 6-K filings to the SEC and TASE.

The market context for these communications includes:

• Current Market Cap: Approximately $8.16 million to $8.18 million.
• Shares Outstanding: 881.39 million.
• Average Trading Volume: 812,647 shares.
• Recent Capital Raise: A Private Placement of $1.5 million was completed.

The company's Price-to-Sales Ratio for December 2024 stood at 26.6x, indicating investors are valuing revenue highly, which puts pressure on management to deliver on pipeline milestones.

Regulatory engagement with bodies like the FDA for clinical assets

Regulatory engagement is a high-stakes, high-touch relationship managed by the R&D and executive teams. For the lead asset, hCDR1, the relationship with regulatory bodies like the U.S. Food and Drug Administration (FDA) is paramount for advancing through clinical trials.

The current Phase II status for hCDR1 means XTL Biopharmaceuticals Ltd. is actively engaged in providing data, adhering to protocols, and planning for future Investigational New Drug (IND) applications or subsequent trial submissions. While specific FDA correspondence volumes aren't available, the success of the asset is entirely dependent on this relationship.

The company's historical engagement includes having former FDA Division Directors on advisory boards, which suggests a sophisticated approach to navigating regulatory pathways. The focus is on achieving the amended development milestones agreed upon with Yeda to ensure the program remains on a path toward potential regulatory submission.

Finance: draft 13-week cash view by Friday.

XTL Biopharmaceuticals Ltd. (XTLB) - Canvas Business Model: Channels

You're looking at how XTL Biopharmaceuticals Ltd. (XTLB) gets its value propositions-both the drug IP and the web data services-to the end-users or partners. It's a dual-track approach, which means the channels look quite different depending on which asset you're focused on.

Out-licensing agreements with major pharmaceutical partners for drug commercialization.

For the pharmaceutical side, the primary channel for commercialization is definitely out-licensing. XTL Biopharmaceuticals Ltd. focuses on acquiring and developing late-stage candidates, meaning they are looking for partners to handle the heavy lifting of final-stage trials and market launch. Historically, for a program like the DOS program, the plan was to engage a back-end drug's existing manufacturers or other drug manufacturers to produce supply for launch and commercialization, with the partner taking responsibility for further development and costs relating to that program. Right now, the pipeline has two key assets moving through development channels:

• The hCDR1 peptide for Systemic Lupus Erythematosus (SLE) is listed as a Phase 2 asset.
• Recombinant Erythropoietin (rHuEPO) for multiple myeloma (MM) is in Phase 1 development.

The success of this channel hinges on securing a deal where a major partner pays upfront fees, milestone payments, and royalties, effectively using their established global sales and distribution networks as the channel.

Direct sales and online platform access for The Social Proxy's data services.

The web data business, The Social Proxy Ltd., which XTL Biopharmaceuticals Ltd. owns 100% of, operates through a different set of channels. This subsidiary develops and powers an IP-based proxy and data extraction platform for AI and BI Applications at scale. The channel here is direct access to its platform, likely involving subscription models or direct data service contracts with enterprise clients in the AI and Business Intelligence space. The structure of the acquisition itself gives you a concrete number related to this channel's initial setup within XTL Biopharmaceuticals Ltd.: the shareholders of The Social Proxy Ltd. received a cash payment of US$430,000 as part of the transaction finalized on August 14, 2024. The Social Proxy shareholders also received ADSs representing 44.6% of XTL Biopharmaceuticals Ltd.'s issued and outstanding share capital post-issuance.

Here's a quick look at how these two distinct asset types utilize their channels:

Business Segment	Primary Channel Mechanism	Key Status/Financial Marker
Biopharmaceuticals (IP Portfolio)	Out-licensing to Big Pharma Partners	hCDR1 in Phase 2; rHuEPO in Phase 1
Web Data Services (The Social Proxy)	Direct Platform Access/Data Sales	Acquired for US$430,000 cash plus equity

Investor communications via SEC filings and press releases.

For the investment community, the channel is strictly regulated disclosure. XTL Biopharmaceuticals Ltd. is traded on the Nasdaq Capital Market (XTLB) and the Tel Aviv Stock Exchange (TASE: XTLB.TA). You can track their communications through required filings. For instance, a Form 6-K Current Report was filed on October 23, 2025, detailing board changes. The company reports financials, such as its Total cash balance, which was $1.7M, and its Market Cap stood at $10.1M with 881M shares outstanding as of June 2025. The trailing 12-month revenue as of December 31, 2024, was $451K. These filings are the official conduit for information.

Clinical trial sites and investigators for drug development.

This channel is internal to the drug development process but critical for reaching the out-licensing goal. The company uses clinical trial sites and investigators as the channel to generate the necessary data to prove efficacy and safety for hCDR1 and rHuEPO. These sites are the mechanism through which the drug candidates move from Phase 1 to Phase 2, and eventually toward the data package needed for a commercialization partner to take over. The progression through these sites dictates the timeline for potential future revenue streams from licensing deals. Finance: draft 13-week cash view by Friday.

XTL Biopharmaceuticals Ltd. (XTLB) - Canvas Business Model: Customer Segments

You're looking at the customer base for XTL Biopharmaceuticals Ltd. (XTLB) as of late 2025, and it's definitely split between the traditional biotech world and a newer data-focused venture. The first key group involves large pharmaceutical companies. These partners are interested because XTL Biopharmaceuticals Ltd. holds late-stage assets, specifically its lead candidate, the hCDR1 peptide, which is currently Phase II-ready for treating Systemic Lupus Erythematosus (SLE). Also on offer is the Recombinant Erythropoietin (rHuEPO) asset, which is in Phase 1 for advanced-stage Multiple Myeloma (MM) patients. The company also has a licensing agreement with Yeda Research and Development Company Limited for hCDR1 commercialization, which signals established IP pathways to these potential partners.

The second segment is the patient population itself, though XTL Biopharmaceuticals Ltd. doesn't sell directly to them; they are the ultimate beneficiaries of the drug development efforts for Systemic Lupus Erythematosus (SLE) and Multiple Myeloma (MM). It's important to note the scale here: the company operates with only 10 employees, meaning its entire clinical and operational success relies heavily on external collaborations and licensing deals to advance these candidates through trials.

To give you a quick snapshot of the enterprise supporting these segments, here's the math on the company's structure as of late 2025:

Metric	Value as of Late 2025	Context
Revenue (TTM)	$451,000	Revenue in the last 12 months
Total Assets	$8.55M	Total assets reported
Shareholders Equity	$5.44M	Shareholders equity reported
Market Capitalization	$8.16M	As of December 5, 2025
Price-to-Sales Ratio	22.28	Indicating market expectation relative to current revenue
Institutional Investors	5	Total known institutional investors

Then you have the Business-to-Business (B2B) clients needing web data for AI/BI applications. This segment stems from XTL Biopharmaceuticals Ltd.'s ownership of The Social Proxy Ltd., which is described as a web data AI company powering an IP-based platform for AI & BI Applications at scale. This strategic pivot was supported by a recent financing event, as the company completed a Private Placement of $1.5 Million, which expanded its IP portfolio into this area. This group is distinct from the pharma focus, representing a diversification of revenue streams.

Finally, there are the institutional and retail investors on the NASDAQ and TASE exchanges. These folks are trading the stock under the ticker XTLB. As of December 5, 2025, the closing price was around $0.85, with a market cap of $8.16M. Investor sentiment is mixed; the short sale ratio was reported at 25.48% on that date, although short interest had recently decreased by 2.42% compared to the previous month. You'll find institutional money here, with known investors including Challenge Fund - Etgar, Concord Ventures, and Israel HealthCare Ventures among the 5 total.

Finance: draft 13-week cash view by Friday.

XTL Biopharmaceuticals Ltd. (XTLB) - Canvas Business Model: Cost Structure

You're looking at XTL Biopharmaceuticals Ltd.'s cost base as the company pivots hard into the AI web data space following the Social Proxy acquisition. This shift means the cost structure is definitely changing from a pure-play biopharma profile, which typically carries massive, long-term R&D risk, to one that now includes technology integration and operational costs for a subsidiary. Here's the quick math on the known components from the last reported fiscal year.

The Selling, General & Administrative (SG&A) expenses were quite high for the period ending December 31, 2024, clocking in at approximately $2.08 million in FY 2024. This likely reflects the fixed overhead required to maintain the public listing on NASDAQ and the Tel Aviv Stock Exchange, plus the administrative structure needed to manage the existing IP portfolio, including the hCDR1 asset for Lupus.

Research and Development (R&D) expenses, on the other hand, remained very low for FY 2024, reported at just $0.1 million. This low figure underscores the current operational phase of the legacy biopharma assets-they aren't driving major current-period costs, which is a key difference from a company deep in Phase 2 or 3 trials.

The transition is cemented by the acquisition cost itself. XTL Biopharmaceuticals Ltd. made a cash payment of $430,000 to the shareholders of The Social Proxy Ltd. as part of the deal finalized in August 2024. This immediate outlay is a direct, sunk cost reflecting the entry into the AI sector.

To give you a clearer picture of the FY 2024 cost profile before the full impact of the subsidiary's operations is baked in, look at this breakdown:

Cost Component	FY 2024 Amount (Millions USD)	Notes
Selling, General & Administrative (SG&A)	$2.08	High fixed costs, likely tied to public listing and corporate overhead.
Research and Development (R&D)	$0.1	Low spend, reflecting the current status of the legacy biopharma IP.
Acquisition Cash Outlay (Social Proxy)	$0.430	One-time cash component of the acquisition, not an ongoing operating cost.
Total Reported Operating Expenses (Excl. Non-Recurring)	$2.18	Sum of SG&A ($2.08M) and R&D ($0.1M) from the income statement.

Now, let's talk about the new operational costs you need to track. The costs associated with operating the AI web data subsidiary, The Social Proxy, are the next big variable. While the acquisition was partially funded by a $1.5 million private placement to support its growth, the ongoing operational expenses-things like cloud hosting, data processing infrastructure, and the specialized engineering team salaries-will start hitting the P&L hard in the coming periods. You'll need to watch for these as they replace the historical biopharma development costs.

Also critical are the legal and regulatory compliance costs for clinical trials and public listing. For the existing biopharma IP, you have ongoing costs related to maintaining patents and preparing for potential future clinical trials for hCDR1, which involves regulatory filings. Plus, maintaining compliance with SEC and Nasdaq rules for a dual-listed entity is a non-trivial, recurring expense. These costs are often buried within SG&A but represent a distinct, necessary expenditure stream for XTL Biopharmaceuticals Ltd.

Here are the key cost drivers you must monitor moving forward:

• Costs to integrate The Social Proxy technology stack.
• Salaries for the newly acquired AI/data science personnel.
• Ongoing legal fees for SEC/Nasdaq reporting requirements.
• Costs to maintain the hCDR1 intellectual property portfolio.
• Regulatory filing fees for any future clinical trial planning.

Finance: draft 13-week cash view by Friday.

XTL Biopharmaceuticals Ltd. (XTLB) - Canvas Business Model: Revenue Streams

You're looking at how XTL Biopharmaceuticals Ltd. (XTLB) is bringing in cash as of late 2025. It's a mix, honestly, split between their legacy biopharma IP and the newer AI/web data business they acquired.

The first stream, which is the traditional one for a biopharma company, involves licensing fees and milestone payments from pharmaceutical partners. While XTL Biopharmaceuticals Ltd. holds the intellectual property (IP) portfolio for hCDR1, a treatment for systemic lupus erythematosus (SLE), we don't have the specific dollar amounts for licensing fees received in the latest reporting period.

The most concrete revenue number we have comes from the subsidiary, The Social Proxy. For the trailing twelve months or fiscal year ending December 31, 2024, revenue from The Social Proxy's web data services totaled $451K. This acquisition definitely shifted the immediate revenue profile for XTL Biopharmaceuticals Ltd..

Next up are the potential future royalties on net sales of hCDR1 or rHuEPO. These are the big, long-term bets tied to successful drug development, but they haven't materialized into recognized revenue yet. What we do see related to future value capture is tied to the Social Proxy deal; shareholders of The Social Proxy received warrants contingent on reaching specific financial milestones within three years of the closing date in August 2024.

Finally, equity financing provides necessary working capital. XTL Biopharmaceuticals Ltd. secured a commitment for an investment of $1.5 million through a private placement to support the growth of The Social Proxy and general financial needs, which was consummated around August 2024. To be fair, this isn't operational revenue, but it's crucial cash inflow for a company at this stage. As part of the acquisition itself, XTL Biopharmaceuticals Ltd. also paid $430,000 in cash to The Social Proxy shareholders.

Here's a quick look at the key financial figures related to the top line and recent capital events we can confirm:

Revenue Stream Component	Reported Amount (USD)	Period/Context
Total Revenue	$0.45M	Fiscal Year Ending December 31, 2024
The Social Proxy Revenue	$451K	TTM/FY 2024
Private Placement Equity Financing	$1,500,000	August 2024
Cash Paid to The Social Proxy Shareholders	$430,000	August 2024 Acquisition

You should track the following potential revenue drivers closely:

• Milestone payments tied to hCDR1 clinical progress.
• Net sales royalties from any future commercialization of hCDR1.
• Revenue growth trajectory of The Social Proxy subsidiary.
• Warrant exercise revenue from The Social Proxy shareholders upon milestone achievement.

Finance: draft 13-week cash view by Friday.